Berlin, 21 October 2019
Accelero Bioanalytics GmbH (“Accelero”) signed an agreement with the gene therapy company CombiGene AB, Lund, Sweden (“CombiGene”) to support the non-clinical development of an Adeno-associated virus (AAV) with its bioanalytical and regulatory expertise.
Berlin, 27 September 2019
Accelero is pleased to announce that the company has been selected as a sustaining member of the CONELIS network life science. The CONELIS network accumulates top-class consulting services for the biotechnology and pharmaceutical industry.
Berlin, 04 June 2019
Accelero is pleased to announce that the company participates as a partner organization in the Marie Curie TRAIN-HEART consortium funded by the European Commission.
Accelero Bioanalytics GmbH, a Berlin-based GLP certified bioanalytical service provider, announces today that the GLP certificate first issued in 2016 has now been renewed by the competent authority for another three years. The re-inspection has been conducted in November 2018.
The company is pleased to initiate its first formal clinical study at one of the breast cancer centres in Berlin, Germany. The study is entitled “Post-operative wound fluid collected from female breast cancer patients” and has been approved by the clinical ethics committee.
Acccelero Bioanalytics GmbH, a GLP certified contract research laboratory in Berlin, Germany, announces today the publication of the supplementary website binding-assay.com.
Accelero Bioanalytics GmbH is a GLP certified contract research service provider for regulatory drug development, and maintains biosafety level 2 laboratories in compliance with ICH GCP regulations.
Acelero Bioanalytics, a GLP certified test facility based in Berlin (Germany), notifies today that the Good Laboratory Practice (GLP) "Summer Seminar" series first launched in 2016 will be continued into its third year.
Office and Management:
Accelerō® Bioanalytics GmbH
Schulzestrasse 20
13187 Berlin
GERMANY
| +49 30 610 910 300 (Office) | |
| service(at)accelero-bioanalytics.com |